AbsciABSI
ABSI logo
Fair Value
US$12.4
Share price26 Jun
US$11.546.9% undervalued intrinsic discount
Loading
1Y347.29%
7D1.67%

Endometriosis And Hair Loss Therapies Will Unlock Long-Term Value Through AI-Driven Biologic Development

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
04 Dec 25
Updated
26 Jun 26
Views
115
Not Invested

Fair Value vs Share Price

US$12.4
vs US$11.546.9% undervalued intrinsic discount
PastFuture-113m30m2019202120232025202620272029Revenue US$29.7mEarnings US$5.6m
152.9%
Revenue growth
18.9%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Absci

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet with slight risk.

Market capUS$2.0b
PB11.4x
Estimated Growth48.5%
Dividend YieldN/A
Full analysis

CEO & management

Sean McClain
CEO
3.3yrs
CEO Tenure

A clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.